

Update: Multibagger Portfolio

Security	ISIN	Entry	Current Price	Performace
Digital Ocean Holdings	US25402D1028	\$25.12	\$43.33	+72.49%
Goosehead Insurance	US38267D1090	\$34.34	\$96.46	+180.90%
Roku	US77543R1023	\$39.85	\$80.07	+100.93%
Sino Biopharma	KYG8167W1380	\$0.59	\$0.48	- 18.64%
Upstart Holdings	US91680M1071	\$12.76	\$53.13	+316.38
Varonis Systems	US9222801022	\$23.94	\$59.43	+148.25%

The portfolio was introduced as a New Year's special, and therefore all positions were bought on the first trading day of the year, January 2, 2023.

Today, I'd like to take a quick look at the holdings in the Multibagger Portfolio. I won't be offering any advice on whether to buy or sell these positions, as that would go against the portfolio's rules. However, it's important to remind you that you are the manager of your portfolio. So, if you decide to sell a position, you'll only know in hindsight if that was the right choice—such is the nature of investing.

Digital Ocean EBITDA is expected to increase by around 50% over the next two years, though the stock is still not exactly cheap. As with most holdings, much will depend on the market's risk tolerance.

Goosehead Insurance I still find the business model highly compelling; management adapts quickly to challenges, and EBITDA is expected to double over the next two years. So why not make an exception and buy more shares? First, conditions can change—over the past 24 months, they've notably shifted twice for this company (once negatively, then positively). Second, the stock remains very highly valued, even accounting for growth, with a 2026 P/E ratio of 45.

Roku If the company reaches its anticipated profitability in the next two years, a bullish outlook would be warranted. If not, the stock could easily halve again. It's essential to remember that the environment has changed

significantly in the last few years. Roku remains a high-risk bet, and it should be treated as such.

Sino Biopharma Although Sino Biopharma has benefited somewhat from the positive sentiment in the broader Chinese market, I am currently down over 18 percent on the stock. Fundamentally, I like the company, but whether this is reflected in the stock price will depend on whether foreign and domestic investors become more willing to invest in China/Hong Kong again.

Upstart Upstart could potentially benefit from further interest rate-cut expectations, but the recent upward movement likely has some "squeeze" dynamics due to short-covering. The "AI factor" has receded, and the stock is now likely to behave solely as a reflection of the credit environment.

Varonis I could interpret recent insider buys as suggesting some takeover speculation, though since I won't be buying more (per the rules), we can simply view this as a "positive signal." Business performance is strong, with EBITDA projected to nearly triple by 2026. However, this stock is also quite ambitiously valued, and a single poor quarterly result could easily halt its upward trajectory. This is true for many companies in the Factor 10 Portfolio, which is why they are kept separate from the standard portfolio actions—the volatility is simply too high to manage with a conventional stop-loss strategy.

Our Multibagger Portfolio





17 TradingView